How Crizotinib Works

How does it work in  ALK+gene?

Advances in genetic research have revealed that non-small cell lung cancer (NSCLC) is not a single disease, but rather many types of cancer with specific genetic differences. Because of these small but important differences, lung cancer medicines that target specific genes, such as anaplastic lymphoma kinase (ALK), can be developed.

Everyone has the ALK gene in their cells. When a part of it breaks off and reattaches in the wrong way, it becomes an abnormal ALK gene. This may cause the cell to multiply out of control and cause a type of lung cancer to grow. This type of lung cancer is called ALK-positive (ALK+) NSCLC.

CRIZITONIB treats ALK+ NSCLC that has spread to other parts of the body. By blocking the action of the abnormal ALK gene, CRIZITONIB may shrink or slow the growth of tumors.

How does it work  in  ROS 1 Positive?

The ROS1 gene makes a protein called ROS, which is found within the membrane of human cells. The ROS protein plays an important role in cell growth and cell specialization. Abnormalities in in the ROS1 gene can lead to a type of lung cancer known as non-small cell lung cancer (NSCLC).

About 1% to 2% of individuals with NSCLC have an abnormality in which the ROS1 gene is fused to parts of another gene. So-called “ROS1 translocations” are more common in lung cancer patients who are nonsmokers and relatively young (average age of 50 years)..

In normal cells, the ROS1 gene makes a protein that regulates cell growth and division. When the ROS1 gene fuses with another gene, the mutated DNA sequence creates an abnormal protein that can cause unregulated cell growth, leading to the development of cancer. The ROS protein and a protein called ALK have similar structure and function.

Crizotinib is an inhibitor of receptor tyrosine kinases ROS1 .Crizotinib demonstrated concentration-dependent inhibition of ROS1 .It works by blocking the action of the abnormal ROS 1 gene, CRIZITONIB may shrink or slow the growth of tumors.

How does it work in  ALK+gene?

Advances in genetic research have revealed that non-small cell lung cancer (NSCLC) is not a single disease, but rather many types of cancer with specific genetic differences. Because of these small but important differences, lung cancer medicines that target specific genes, such as anaplastic lymphoma kinase (ALK), can be developed.

Everyone has the ALK gene in their cells. When a part of it breaks off and reattaches in the wrong way, it becomes an abnormal ALK gene. This may cause the cell to multiply out of control and cause a type of lung cancer to grow. This type of lung cancer is called ALK-positive (ALK+) NSCLC.

CRIZITONIB treats ALK+ NSCLC that has spread to other parts of the body. By blocking the action of the abnormal ALK gene, CRIZITONIB may shrink or slow the growth of tumors.

How does it work  in  ROS 1 Positive?

The ROS1 gene makes a protein called ROS, which is found within the membrane of human cells. The ROS protein plays an important role in cell growth and cell specialization. Abnormalities in in the ROS1 gene can lead to a type of lung cancer known as non-small cell lung cancer (NSCLC).

About 1% to 2% of individuals with NSCLC have an abnormality in which the ROS1 gene is fused to parts of another gene. So-called “ROS1 translocations” are more common in lung cancer patients who are nonsmokers and relatively young (average age of 50 years)..

In normal cells, the ROS1 gene makes a protein that regulates cell growth and division. When the ROS1 gene fuses with another gene, the mutated DNA sequence creates an abnormal protein that can cause unregulated cell growth, leading to the development of cancer. The ROS protein and a protein called ALK have similar structure and function.

Crizotinib is an inhibitor of receptor tyrosine kinases ROS1 .Crizotinib demonstrated concentration-dependent inhibition of ROS1 .It works by blocking the action of the abnormal ROS 1 gene, CRIZITONIB may shrink or slow the growth of tumors.